Recent News

Study Finds Zanubrutinib Active in CLL or Small Lymphocytic Lymphoma

Results of Phase III SEQUOIA Trial of Zanubrutinib in CLL

Early-Phase Results With CD19-Directed Immunotherapy for CLL

Early Results With Chemotherapy-Free Triplet Regimen in Resistant CLL

Ibrutinib and Venetoclax in Treatment of Resistant CLL

Proof-of-Concept Trial of BTK Inhibitor in Advanced B-Cell Malignancies

ASH 2019: Extended Analysis of MURANO Trial of Venetoclax/Rituximab in CLL

ASH 2019: First-Line Ibrutinib and Venetoclax in Previously Treated CLL

ASH 2019: Updated Trial Results With Ibrutinib and Rituximab in CLL

ASH 2019: Acalabrutinib Combination Therapy and Monotherapy in Treatment-Naive CLL

ASH 2019: Acalabrutinib Combination Therapy for Previously Untreated CLL

Study Reports Early-Stage Impairment of Neutrophil Activity With Ibrutinib for CLL

FDA Approves Indication for Acalabrutinib in Chronic Lymphocytic Leukemia

Prognostic Value of Residual Lymphadenopathy After Chemoimmunotherapy for CLL

Weight Gain With Ibrutinib Treatment in Patients With CLL

Aging and Stereotypic B-Cell Receptors Associated With CLL

Using Minimal Residual Disease Detection to Monitor Outcomes in CLL Treatment

First-in-Human Study of CD200 Blockade With Samalizumab in CLL

Update on Resistance to Targeted Therapies in CLL

STIM1 Targeting as a Novel Therapy for Patients With CLL

SOHO 2019: Novel Reversible BTK Inhibitor Therapy for Chronic Lymphocytic Leukemia

SOHO 2019: ‘More Questions Than Answers’ in CLL Therapy

Case of Cranial Aspergillosis in a Patient Receiving Ibrutinib for CLL

Extended Ibrutinib Treatment in RESONATE CLL Trial

ALPINE Trial: Bruton’s Tyrosine Kinase Inhibitor in Resistant CLL

Managing Toxicity With Duvelisib in CLL: Dose Reductions or Interruptions

Venetoclax Plus Obinutuzumab in Patients With Untreated CLL

Epigenetic Diversity in CLL

Acalabrutinib Plus Obinutuzumab in Resistant CLL: 3-Year Follow-up

Final Results of COMPLEMENT 1 Trial: Ofatumumab and Chlorambucil in Untreated CLL

Potential Prognostic Markers in CLL: NOTCH1 Pathway Mutations

Atrial Fibrillation After Treatment With Ibrutinib in Patients With CLL

Treatment of Resistant CLL With Acalabrutinib

Acalabrutinib Granted Breakthrough Therapy Designation in CLL

CLL14 Trial: Paired With Obinutuzumab, Venetoclax Versus Chlorambucil in CLL

Acalabrutinib in Relapsed or Refractory CLL

CLL12 Trial: Ibrutinib Improves Outcomes in Early-Stage CLL

RESONATE2 Update on First-Line Ibrutinib in Older Patients With CLL/SLL

Secondary Cancers and BTK Inhibitors for CLL

Umbralisib in Kinase Inhibitor–Intolerant CLL

Method for Selecting Potential Ibrutinib-Based Combinations in CLL

CD19-Directed Immunotherapy for Relapsed or Refractory CLL